8-K: Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Biotech Showcase

Cellectar Biosciences plans to highlight its 2025 strategic initiatives, including advancing iopofosine I 131 and radiotherapeutic assets, at the Biotech Showcase during the JP Morgan Healthcare Conference.

Summary

• Cellectar Biosciences will present its 2025 strategic initiatives at the Biotech Showcase during the JP Morgan Healthcare Conference.
• The company plans to advance iopofosine I 131, a radioconjugate monotherapy, through strategic partnerships and other approaches.
• Cellectar is finalizing a confirmatory study and pathway for US FDA accelerated approval and EMA Prime marketing authorization for iopofosine I 131.
• The company is also advancing radiotherapeutic assets, including alphaand Auger-emitting radioconjugates, into Phase 1/2a solid tumor studies.
• Iopofosine I 131 achieved an 83.6% overall response rate (ORR) in the Phase 2 CLOVER-WaM study for relapsed/refractory Waldenstrom's Macroglobulinemia.
• The confirmatory study for iopofosine is expected to be a comparator, randomized controlled study with 40-60 patients per arm, with full patient enrollment projected within 18 months of the first patient admitted.
• Cellectar anticipates alignment with the FDA in the first half of 2025.
• The company's cash runway extends into the fourth quarter of 2025.
• Cellectar plans to file an Investigational New Drug (IND) application for CLR 121225 in the first quarter of 2025.
• A Phase 1b/2a dose finding study in triple-negative breast cancer is planned for CLR 121125, which has already received IND clearance.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with promising clinical results and strategic plans. However, the need for potential future capital raises and the inherent risks in drug development temper the overall sentiment.

Positives

• Iopofosine I 131 achieved an 83.6% ORR in the Phase 2 CLOVER-WaM study, exceeding the primary endpoint.
• The company is actively pursuing accelerated approval from the FDA and conditional marketing authorization from the EMA for iopofosine I 131.
• Cellectar has a novel PDC platform for targeted delivery of radiotherapeutics.
• CLR 121225 and CLR 121125 have shown promising results in preclinical studies.
• CLR 121125 has received IND clearance, and a Phase 1b/2a study is planned.
• The company's cash runway extends into the fourth quarter of 2025.

Risks

• The company needs to raise additional capital to continue its development programs.
• The development of new drugs involves a high degree of risk, including uncertainties related to clinical trials, regulatory approvals, and competition.
• The company is evaluating the timing of study initiation for both CLR 121225 and CLR 121125.

Future Outlook

Cellectar is focused on advancing iopofosine I 131 towards regulatory approval and developing its radioconjugate PDC programs for solid tumors. The company is assessing various approaches to bring iopofosine to patients and expects to file an IND for CLR 121225 in the first quarter of 2025.

Management Comments

• 'We remain committed to bringing iopofosine to WM patients, who have limited treatment options for this incurable disease,' said James Caruso, president and CEO of Cellectar.
• 'We believe our ongoing communications with the U.S. Food and Drug Administration (FDA) indicate there is a path forward for a conditional U.S. market approval as part of the accelerated approval process,' said James Caruso, president and CEO of Cellectar.
• 'We believe iopofosine represents a compelling partnership opportunity for many reasons including the results observed from our clinical studies,' said Mr. Caruso.

Industry Context

Cellectar's focus on radioconjugate therapies aligns with the growing interest in targeted cancer treatments. The company's PDC platform could provide a competitive advantage in delivering radiotherapeutics to cancer cells with improved efficacy and reduced off-target effects.

Comparison to Industry Standards

• The 83.6% ORR achieved by Iopofosine I 131 in the CLOVER-WaM study is a strong result compared to standard treatments for relapsed/refractory Waldenstrom's Macroglobulinemia.
• Companies like Novartis with Pluvicto and Endocyte (acquired by Novartis) with Lutathera have demonstrated the potential of radioligand therapies in oncology.
• Cellectar's PDC platform aims to improve upon existing radioligand therapies by enhancing targeted delivery and reducing off-target effects, similar to efforts by other companies in the radiopharmaceutical space such as Actinium Pharmaceuticals and Fusion Pharmaceuticals.

Stakeholder Impact

• Positive impact on patients with Waldenstrom's Macroglobulinemia and other cancers if iopofosine I 131 and other radioconjugates are successfully developed and commercialized.
• Potential benefits for shareholders through increased company value.
• Opportunities for employees in the development and commercialization of new cancer therapies.

Next Steps

• Finalizing confirmatory study and pathway for US FDA accelerated approval and EMA Prime marketing authorization for iopofosine I 131.
• Advancing radiotherapeutic assets, including alphaand Auger-emitting radioconjugates, into Phase 1/2a solid tumor studies.
• Filing an Investigational New Drug (IND) application for CLR 121225 in the first quarter of 2025.
• Evaluating the timing of study initiation for both CLR 121225 and CLR 121125.
• Alignment with the FDA in the first half of 2025.

Key Dates